330350.KQ Withuspharmaceutical Co.Ltd

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
6,370 KRW
Close of Oct 31, 2026
5,910 11,950
Market cap
KRW 84.1B
P/E
10.5x
P/B
0.81x
ROE
11.4%
Dividend yield
-
Fundamental score
2.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 330350.KQ undervalued?

Graham number
Price6,370
Graham value10,347
Discount38.4%

330350.KQ trades 38.4% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Withuspharmaceutical Co.Ltd fundamental analysis

14 of 22 checks passed

ROE 1/2

Moderate return on equity (11.4%), between 10% and 20%.

ROA 1/1

Return on assets (8.2%) is above the industry median (1.4%).

Profit Consistency 2/2

Profitable for 9 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (3.8%) is not above the 5-year average (21.6% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (3.8%) is above the industry median (1.8%).

Revenue Growth 2/2

Revenue grew 18.1% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 1/1

PE (10.5x) is below the market median (11.3x).

PE vs Industry 1/1

PE (10.5x) is below the industry median (11.4x).

PBV 1/1

Price to book (0.8x) is below the industry median (0.9x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 8.5, limit 22.5).

PEG 1/1

PEG on 5-year earnings growth is 0.49, growth is cheap.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Withuspharmaceutical Co.Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Withuspharmaceutical Co.Ltd

WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products. The company wa…

Full company profile